Based on the provided trial data, I cannot definitively identify specific medications to list and describe, as the source text only mentions general categories of treatments:

PD-1/PD-L1 targeted agents
These are immunotherapy medications that help the immune system recognize and fight cancer cells. They work by blocking proteins called PD-1 or PD-L1 that can prevent the immune system from attacking cancer cells.

Immunotherapy (IO) treatment
This refers to treatments that boost the body’s natural defenses to fight bladder cancer. It works by helping your immune system to better recognize and destroy cancer cells.

Note: The trial appears to be studying treatments for metastatic bladder cancer, but specific medication names are not provided in the source data.

Urothelial cancer – A type of cancer that begins in the cells that line the urinary system, most commonly starting in the bladder. It develops when cells in the urothelial lining start growing abnormally and form tumors. The cancer typically starts in the bladder’s inner lining and can spread to deeper tissue layers over time. This disease can affect any part of the urinary tract, including the renal pelvis, ureters, and urethra. The condition usually develops gradually, with cells becoming increasingly abnormal before turning into cancer.